Franziska Duckstein

Brandenburg An Der Havel, BB, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Relating Improvement in Gastrointestinal (CFAbd-Score©) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients.

Relating Improvement in Gastrointestinal (CFAbd-Score©) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients.

Journal: Pediatric pulmonology

Published: August 15, 2025

Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologist's focus.

Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologist's focus.

Journal: Klinische Padiatrie

Published: May 06, 2025

The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor.

The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor.

Journal: Journal of pediatric gastroenterology and nutrition

Published: January 09, 2025

Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.

Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: December 20, 2024

Validation of the CFAbd-Score.kidⒸ, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosis.

Validation of the CFAbd-Score.kidⒸ, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: October 30, 2024

The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor - first results.

The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor - first results.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: July 22, 2024

Chronic rhinosinusitis in people with CF, a rapidly changing field.

Chronic rhinosinusitis in people with CF, a rapidly changing field.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: April 02, 2024

Cross-cultural adaptation and validation of the CFAbd-Score for gastrointestinal symptoms in patients with cystic fibrosis.

Cross-cultural adaptation and validation of the CFAbd-Score for gastrointestinal symptoms in patients with cystic fibrosis.

Journal: Jornal de pediatria

Published: March 11, 2024

Scoring Abdominal Symptoms in People with Cystic Fibrosis.

Scoring Abdominal Symptoms in People with Cystic Fibrosis.

Journal: Journal of clinical medicine

Published: February 02, 2024

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: July 05, 2023

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.

Journal: Frontiers in pharmacology

Published: April 17, 2023

Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.

Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.

Journal: Frontiers in pharmacology

Published: March 07, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026